Breakdown | |||||
TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
60.08M | 59.84M | 55.17M | 40.01M | 31.29M | 29.08M | Gross Profit |
27.43M | 26.27M | 22.00M | 16.46M | 12.89M | 11.34M | EBIT |
15.23M | 14.45M | 12.76M | 8.79M | 6.38M | 4.84M | EBITDA |
15.97M | 15.32M | 13.22M | 9.44M | 8.05M | 5.86M | Net Income Common Stockholders |
9.42M | 8.89M | 7.69M | 6.08M | 5.13M | 3.12M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
8.13M | 12.05M | 10.40M | 6.65M | 5.26M | 3.63M | Total Assets |
66.27M | 68.23M | 65.55M | 55.56M | 48.37M | 45.17M | Total Debt |
4.57M | 3.38M | 4.31M | 3.51M | 1.44M | 1.94M | Net Debt |
-3.56M | -8.67M | -6.09M | -3.14M | -3.82M | -1.70M | Total Liabilities |
12.07M | 12.69M | 15.97M | 12.21M | 9.27M | 9.53M | Stockholders Equity |
54.21M | 54.89M | 49.25M | 43.48M | 39.10M | 35.64M |
Cash Flow | Free Cash Flow | ||||
9.37M | 6.45M | 7.63M | 2.63M | 3.86M | 3.45M | Operating Cash Flow |
10.37M | 8.09M | 8.42M | 3.15M | 4.51M | 4.20M | Investing Cash Flow |
-2.03M | -1.64M | -782.43K | -1.11M | -652.62K | -753.41K | Financing Cash Flow |
-8.53M | -4.80M | -3.88M | -648.95K | -2.24M | -3.05M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
70 Outperform | AU$219.24M | 23.04 | 18.04% | 2.44% | 6.00% | 10.26% | |
51 Neutral | $2.04B | -1.15 | -21.24% | 3.95% | 2.91% | -30.44% | |
$306.23M | ― | -133.28% | ― | ― | ― | ||
$76.87B | 28.01 | 15.38% | 1.73% | ― | ― | ||
79 Outperform | AU$57.06B | 28.38 | 25.23% | 1.31% | 10.54% | 38.69% | |
55 Neutral | $176.66M | ― | -33.75% | ― | -11.19% | -174.51% | |
54 Neutral | AU$123.55M | ― | -5.63% | ― | -11.96% | 7.50% |
XRF Scientific Limited announced a change in the director’s interest, with Vance Stazzonelli acquiring 10,000 ordinary shares, increasing his total to 850,000 shares. This change, executed through a combination of off-market and on-market trades, reflects ongoing adjustments in the company’s leadership investments, potentially impacting stakeholder perceptions and the company’s market dynamics.
The most recent analyst rating on (AU:XRF) stock is a Buy with a A$2.22 price target. To see the full list of analyst forecasts on XRF Scientific Limited stock, see the AU:XRF Stock Forecast page.
XRF Scientific Limited reported a mixed performance in its March 2025 quarterly trading report, with a 9% decrease in revenue to $13.9 million compared to the previous year, but a 5% increase in profit before tax to $3.4 million. The company continues to see growth potential in international markets, driven by the mining industry and international sales, particularly in Asia, the Americas, and Europe. Despite global trade tensions, XRF remains focused on expanding its international sales and exploring new product developments and M&A opportunities.
XRF Scientific Limited has announced a change in the director’s interest notice, specifically regarding David Brown’s indirect interest in the company’s securities. On March 13 and 14, 2025, Brown acquired 32,000 ordinary shares through an on-market trade, increasing his indirect holdings to 3,466,128 shares. This transaction, valued at $56,960, reflects ongoing adjustments in the company’s leadership investment strategies, potentially impacting stakeholder perceptions and the company’s market positioning.
XRF Scientific Limited announced the quotation of 42,886 ordinary fully paid securities on the ASX, issued under an employee incentive scheme. This move may enhance the company’s market presence and provide additional liquidity, potentially benefiting stakeholders by aligning employee interests with company performance.